All articles by GBI Research

GBI Research

HPV vaccines continue to dominate cancer vaccines landscape

Cancer vaccines are a type of immunotherapy used to either treat existing cancer or prevent the development of cancer. Cancer…
The bioterrorism threat: what power can terrorists wield with microbes?

Infectious diseases kill over 17 million people yearly and the agents that cause them are toxic, widespread and reproducible. These…
GM babies: He Jiankui and the ethics of gene editing

In late November, Shenzhan’s Southern University of Science and Technology researcher He Jiankui announced on YouTube that his research had…
‘Nanocarrier’ brings hope for disease-modifying osteoarthritis drugs

Osteoarthritis is a progressive degenerative disease of the joints thought to affect over 30 million adults in the US. The…
Industry experts believe External Reference Pricing is coming to the US

On October 25, 2018, the Trump administration proposed limiting Medicare’s spending on drugs by implementing an International Pricing Index, which…

Scorpion venom could hold the key to breaching the blood-brain barrier

The Peptides and Proteins Lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical…
Waste not, want not: how exosomes went from trash to trials

Exosomes are cell-derived vesicles that are present in almost all eukaryotic fluids, including blood, urine, cerebrospinal fluid (CSF) and cultured…
Does psychedelic microdosing have true potential in mental health?

Micro-dosing is a growing health phenomenon involving the regular consumption of small doses of psychedelic drugs, usually a tenth of…
Xofluza: prospects for the first FDA-approved flu therapy in 20 years

On October 20 2018, Xofluza (baloxavir marboxil) became the first medicine to achieve FDA approval for the treatment of the…
Will biosimilar launches send Humira tumbling in Europe?

Last week, the EU saw the launch of four different biosimilars of Humira (adalimumab), the best-selling prescription drug in the…